Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

View ORCID ProfileMaría Eugenia Toledo-Romani, View ORCID ProfileMayra García-Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meybis Rodriguez-González, View ORCID ProfileCarmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sanchez-Ramirez, Raúl González-Mugica, Tays Hernández-Garcia, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara, View ORCID ProfileJuliet Enriquez-Puertas, Enrique Noa-Romero, View ORCID ProfileAriel Palenzuela-Diaz, Gerardo Baro-Roman, View ORCID ProfileIvis Mendoza-Hernández, View ORCID ProfileYaima Muñoz, Yanet Gómez-Maceo, Bertha Leysi Santos-Vega, View ORCID ProfileSonsire Fernandez-Castillo, View ORCID ProfileYanet Climent-Ruiz, View ORCID ProfileLaura Rodríguez-Noda, View ORCID ProfileDarielys Santana-Mederos, View ORCID ProfileYanelda García-Vega, Guang Wu-Chen, View ORCID ProfileDelaram Doroud, Alireza Biglari, View ORCID ProfileTammy Boggiano-Ayo, Yury Valdés-Balbín, Daniel García-Rivera, View ORCID ProfileDagmar García-Rivera, View ORCID ProfileVicente Vérez-Bencomo, SOBERANA Research Group
doi: https://doi.org/10.1101/2022.01.01.21268271
María Eugenia Toledo-Romani
1“Pedro Kourí” Tropical Medicine Institute. Av “Novia del Mediodía”, Kv 6 1/2, La Lisa, Habana, 11400, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for María Eugenia Toledo-Romani
Mayra García-Carmenate
2“19 de Abril” Polyclinic. Tulipan Street between Panorama y Oeste, Nuevo Vedado, Plaza de la Revolución, Havana 10400, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mayra García-Carmenate
Leslyhana Verdecia-Sánchez
3Clinic #1. 21 St. and 190, La Lisa. Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzel Pérez-Rodríguez
2“19 de Abril” Polyclinic. Tulipan Street between Panorama y Oeste, Nuevo Vedado, Plaza de la Revolución, Havana 10400, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meybis Rodriguez-González
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Valenzuela-Silva
5Cybernetics, Mathematics and Physics Institute. 15th St #55, Vedado, Plaza de la Revolución, Havana10400, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carmen Valenzuela-Silva
Beatriz Paredes-Moreno
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Belinda Sanchez-Ramirez
6Centre of Molecular Immunology. 15th Ave. and 216 St, Siboney, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raúl González-Mugica
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tays Hernández-Garcia
6Centre of Molecular Immunology. 15th Ave. and 216 St, Siboney, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivette Orosa-Vázquez
6Centre of Molecular Immunology. 15th Ave. and 216 St, Siboney, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianniz Díaz-Hernández
6Centre of Molecular Immunology. 15th Ave. and 216 St, Siboney, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Teresa Pérez-Guevara
7National Civil Defense Research Laboratory. San José de las Lajas, Mayabeque, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliet Enriquez-Puertas
7National Civil Defense Research Laboratory. San José de las Lajas, Mayabeque, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Juliet Enriquez-Puertas
Enrique Noa-Romero
7National Civil Defense Research Laboratory. San José de las Lajas, Mayabeque, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariel Palenzuela-Diaz
8Centre for Immunoassays. 134 St and 25, Cubanacán, Playa, Havana, 11600 Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ariel Palenzuela-Diaz
Gerardo Baro-Roman
8Centre for Immunoassays. 134 St and 25, Cubanacán, Playa, Havana, 11600 Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivis Mendoza-Hernández
9National Clinical Trials Coordinating Center. 5th Ave and 62, Miramar, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ivis Mendoza-Hernández
Yaima Muñoz
9National Clinical Trials Coordinating Center. 5th Ave and 62, Miramar, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yaima Muñoz
Yanet Gómez-Maceo
3Clinic #1. 21 St. and 190, La Lisa. Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bertha Leysi Santos-Vega
2“19 de Abril” Polyclinic. Tulipan Street between Panorama y Oeste, Nuevo Vedado, Plaza de la Revolución, Havana 10400, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonsire Fernandez-Castillo
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sonsire Fernandez-Castillo
  • For correspondence: sfernandez@finlay.edu.cu
Yanet Climent-Ruiz
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yanet Climent-Ruiz
Laura Rodríguez-Noda
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura Rodríguez-Noda
Darielys Santana-Mederos
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Darielys Santana-Mederos
Yanelda García-Vega
6Centre of Molecular Immunology. 15th Ave. and 216 St, Siboney, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yanelda García-Vega
Guang Wu-Chen
10Chengdu Olisynn Biotech. Co. Ltd., and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Delaram Doroud
11Pasteur Institute of Iran. No. 69, Pasteur Ave., Tehran 1316943551, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Delaram Doroud
Alireza Biglari
11Pasteur Institute of Iran. No. 69, Pasteur Ave., Tehran 1316943551, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tammy Boggiano-Ayo
6Centre of Molecular Immunology. 15th Ave. and 216 St, Siboney, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tammy Boggiano-Ayo
Yury Valdés-Balbín
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel García-Rivera
12Laboratory of Synthetic and Biomolecular Chemistry, Faculty of Chemistry, University of Havana, Havana 10400, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dagmar García-Rivera
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dagmar García-Rivera
Vicente Vérez-Bencomo
4Finlay Vaccine Institute. 21st Ave. N° 19810 between 198 and 200 St, Atabey, Playa, Havana, Cuba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vicente Vérez-Bencomo
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background We report results of immunogenicity, safety and reactogenicity of SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial.

Method This phase IIb trial was designed as parallel, multicentre, adaptive, double blind, randomized and placebo-controlled. Subjects (N=810) aged 19-80 years were randomized to receive two doses of the recombinant SARS CoV-2 receptor binding domain (RBD) conjugated to tetanus toxoid (SOBERANA 02) and a third dose of dimeric RBD (SOBERANA Plus) 28 days apart; two production batches of active ingredient of SOBERANA 02 were evaluated. Primary outcome was the percentage of seroconverted subjects with ≥4-fold the anti-RBD IgG concentration. Secondary outcomes were safety, reactogenicity and neutralizing antibodies.

Results Seroconversion rate in vaccinees was respectively 76.3 and 96.8% after two or three doses, compared with 7.3% in placebo group. Anti-RBD IgG increased significantly after first and second dose of SOBERANA 02 respect to placebo group; and the third dose with SOBERANA Plus boosts the response compared to the second dose. Neutralizing IgG antibodies were detected against D614G and VOCs α, β and δ. Specific and functional antibodies were detected at least until 7-8 months after the third dose. The frequency of serious adverse events (AEs) associated with vaccination was very low (0.1%); with only one serious AE consistent with vaccination. Local pain was the most frequent AE.

Conclusions Two doses of SOBERANA 02 were well tolerated, safe an immunogenic in adults aged 19-80 years old. The heterologous combination with a third dose of SOBERANA Plus increased neutralizing antibodies, detectable 7-8 months after finishing the vaccination schedule.

Trial registry https://rpcec.sld.cu/trials/RPCEC00000347

Competing Interest Statement

Authors M.E.T.R., M.G.C., L.V.S., S.P.R, C.V.S, M.T.P.G., J.E.P, E.N.R., A.P.D., G.B.R., I.M.H., Y.M, Y.G.M., B.L.S.V., G.W.C., D.D., A.B., and D.G.R., declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Authors M.R.G., B.P.M., B.S.R., R.G.M., T.H.G., I.O.V., M.D.H., S.F.C., Y.C.R, L.R.N., D.S.M., Y.G.V., T.B.A., Y.V.B., D.G.R., and V.V.B., work at Finlay Vaccine Institute or the Centre of Molecular Immunology, institutions that develop and manufacture the vaccine candidates but they have not received an honorarium for this paper. B.S.R., S.F.C., Y.C.R, L.R.N., D.S.M., Y.V.B., D.G.R., D.G.R. and V.V.B., have filed patent applications related to the vaccine SOBERANA 02.

Clinical Trial

international clinical trial register. https://rpcec.sld.cu/trials/RPCEC00000347

Funding Statement

This work was supported by the Finlay Vaccine Institute, BioCubaFarma and the Fondo Nacional de Ciencia y Tecnica (FONCI-CITMA-Cuba, contract 2020-20)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

ad hoc centralized Research Ethics Committee from the Medical Sciences University, Faculty of Medicine Manuel Fajardo, Havana, designed by the Health Innovation Committee from the Cuban Ministry of Health (MINSAP)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 05, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
María Eugenia Toledo-Romani, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meybis Rodriguez-González, Carmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sanchez-Ramirez, Raúl González-Mugica, Tays Hernández-Garcia, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara, Juliet Enriquez-Puertas, Enrique Noa-Romero, Ariel Palenzuela-Diaz, Gerardo Baro-Roman, Ivis Mendoza-Hernández, Yaima Muñoz, Yanet Gómez-Maceo, Bertha Leysi Santos-Vega, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanelda García-Vega, Guang Wu-Chen, Delaram Doroud, Alireza Biglari, Tammy Boggiano-Ayo, Yury Valdés-Balbín, Daniel García-Rivera, Dagmar García-Rivera, Vicente Vérez-Bencomo, SOBERANA Research Group
medRxiv 2022.01.01.21268271; doi: https://doi.org/10.1101/2022.01.01.21268271
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
María Eugenia Toledo-Romani, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meybis Rodriguez-González, Carmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sanchez-Ramirez, Raúl González-Mugica, Tays Hernández-Garcia, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara, Juliet Enriquez-Puertas, Enrique Noa-Romero, Ariel Palenzuela-Diaz, Gerardo Baro-Roman, Ivis Mendoza-Hernández, Yaima Muñoz, Yanet Gómez-Maceo, Bertha Leysi Santos-Vega, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanelda García-Vega, Guang Wu-Chen, Delaram Doroud, Alireza Biglari, Tammy Boggiano-Ayo, Yury Valdés-Balbín, Daniel García-Rivera, Dagmar García-Rivera, Vicente Vérez-Bencomo, SOBERANA Research Group
medRxiv 2022.01.01.21268271; doi: https://doi.org/10.1101/2022.01.01.21268271

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)